Sökning: "binding specificities"
Visar resultat 31 - 35 av 62 avhandlingar innehållade orden binding specificities.
31. RNA-protein complexes as autoantigens : cell and molecular biology of Ro/SSA and disease associations of anti-Ro/SSA antibodies
Sammanfattning : Autoantibodies to the Ro/SSA and La/SSB antigens are present in sera from patients with Sjögren's syndrome (SS) and systemic lupus erythematosus (SLE). The Ro/SSA autoantigen consists of a 52kD and a 60kD protein, complexed with one of four small RNAs. The La protein can also associate with the complex. LÄS MER
32. The MHC genes: variation and impact on life-history traits in house sparrwos
Sammanfattning : In birds the major histocompatibility complex (MHC) organization differs both among and within orders. Galliformes often have simple arrangements with few transcribed MHC genes whilst many songbirds (Passeriformes) have a complex arrangement with many MHC genes and also presence of pseudo-genes. LÄS MER
33. Monoclonal antibodies against Haemophilus lipopolysaccharides
Sammanfattning : The genus Haemophilus comprises a group of gram-negative bacteria with fastidious growth requirements. Among the Haemophilus species, H. influenzae and H. ducreyi are the most important in human medicine. LÄS MER
34. Molecular characterization of the Ro52 autoantigen and its disease related epitopes
Sammanfattning : The presence of high titers of autoantibodies in patient sera is characteristic for the autoimmune disorder Sjögren s syndrome. The major targets for these autoantibodies are three intracellular proteins Ro52, Ro60 and La. It is still unclear why these proteins become targets for the immune system, and how this autoreactivity is triggered. LÄS MER
35. Dissection of HIV-1 Env-specific B cell responses in nonhuman primates
Sammanfattning : Vaccine-induced protection is generally mediated by long-lived antigen-specific B cell responses. Most licensed vaccines target pathogens that display relatively low variability, but for highly variable pathogens, such as HIV-1, vaccine development is more challenging. LÄS MER